MARYLAND, July 23 (Reuters): Biotech experts and industry executives are calling plans by the US Food and Drug Administration-hit by job cuts last year-to hire thousands of employees and update clinical-trial standards encouragingly, but want assurance that politics will not interfere in the agency's drug-review process.
"Regulatory predictability is ultimately what keeps promising science from being abandoned before it reaches patients," said John Guy, policy director at the Incubate Coalition, a venture capital advocacy group.
"The agency's current priority should be rebuilding durable scientific expertise."
Under Robert F Kennedy Jr, President Donald Trump's health secretary, the FDA has lost more than 3,000 employees, including key division heads, through cuts and departures.
Biotech experts want FDA drug reviews based on science, not politics
FE Team | Published: July 23, 2026 22:26:19
Biotech experts want FDA drug reviews based on science, not politics
Share if you like